Nuvation Bio Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NUVB research report →
Companywww.nuvationbio.com
Nuvation Bio Inc. , a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6.
- CEO
- David T. Hung
- IPO
- 2020
- Employees
- 273
- HQ
- New York City, NY, US
Price Chart
Valuation
- Market Cap
- $1.57B
- P/E
- -10.73
- P/S
- 10.95
- P/B
- 4.90
- EV/EBITDA
- -10.47
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 91.64%
- Op Margin
- -104.99%
- Net Margin
- -102.06%
- ROE
- -44.10%
- ROIC
- -27.90%
Growth & Income
- Revenue
- $62.90M · 698.96%
- Net Income
- $-204,627,000 · 63.97%
- EPS
- $-0.60 · 71.56%
- Op Income
- $-213,064,000
- FCF YoY
- -33.09%
Performance & Tape
- 52W High
- $9.75
- 52W Low
- $1.57
- 50D MA
- $4.58
- 200D MA
- $5.09
- Beta
- 1.52
- Avg Volume
- 4.42M
Get TickerSpark's AI analysis on NUVB
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 17, 26 | Wentworth Kerry | other | 36,750 |
| Apr 17, 26 | Wentworth Kerry | other | 36,750 |
| Apr 17, 26 | Wentworth Kerry | sell | 36,750 |
| Apr 17, 26 | Liu Dongfang | other | 50,000 |
| Apr 17, 26 | Liu Dongfang | other | 50,000 |
| Apr 17, 26 | Liu Dongfang | sell | 50,000 |
| Apr 6, 26 | Wentworth Kerry | other | 100,000 |
| Apr 6, 26 | Wentworth Kerry | other | 100,000 |
| Apr 6, 26 | Wentworth Kerry | other | 100,000 |
| Apr 6, 26 | Wentworth Kerry | other | 100,000 |
Our NUVB Coverage
We haven't published any research on NUVB yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate NUVB Report →